Literature DB >> 20457281

B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.

Marie-Michèle Varin1, Laëtitia Le Pottier, Pierre Youinou, Damien Saulep, Fabienne Mackay, Jacques-Olivier Pers.   

Abstract

Sjögren's syndrome (SS) is an autoimmune epithelitis hallmarked by a destruction of epithelial cells, the subsequent lymphocytic infiltration of exocrine glands and their ensuing dryness. Given the prominent role currently assigned to B cells in SS, it is not surprising that the B cell activating factor belonging to the Tumor Necrosis Factor family (BAFF) is involved in its pathogenesis. When overexpressed, this cytokine leads to self-reactive B cells emergence at the transitional B-cell stage. BAFF overexpression that has been observed in SS, is associated with B-cell tolerance breakdown and autoantibody production. Furthermore, BAFF is responsible for the abnormal distribution of B cells subsets and B-cell hyperactivity described in the blood. In the salivary glands, a minority of B-cell clusters represent ectopic germinal center cells, while the majority manifest features consistent with transitional type 2 (T2) and marginal-zone (MZ)-like B cells. Interestingly, both types of B-cell cluster include autoreactive B cells and BAFF is associated with expansion of T2 B cells and MZ-like B cells in the salivary glands. Finally, BAFF plays a major role in B-cell repopulation after their depletion by rituximab in SS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457281     DOI: 10.1016/j.autrev.2010.05.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  27 in total

Review 1.  Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR.

Authors:  Shu Man Fu; Umesh S Deshmukh; Felicia Gaskin
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

2.  Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Authors:  D Saadoun; B Terrier; J Bannock; T Vazquez; C Massad; I Kang; F Joly; M Rosenzwajg; D Sene; P Benech; L Musset; D Klatzmann; E Meffre; P Cacoub
Journal:  Arthritis Rheum       Date:  2013-04

Review 3.  The autoimmune side of heart and lung diseases.

Authors:  Nancy Agmon-Levin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 4.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 6.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

7.  The Expression of BAFF Is Controlled by IRF Transcription Factors.

Authors:  Maria Sjöstrand; Alina Johansson; Lara Aqrawi; Tomas Olsson; Marie Wahren-Herlenius; Alexander Espinosa
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

8.  Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses.

Authors:  Marta Cuenca; Xavier Romero; Jordi Sintes; Cox Terhorst; Pablo Engel
Journal:  J Immunol       Date:  2015-12-14       Impact factor: 5.422

9.  Dendritic cell status modulates the outcome of HIV-related B cell disease progression.

Authors:  Johanne Poudrier; Michel Roger
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

10.  Follicular dendritic cells in health and disease.

Authors:  Mohey Eldin M El Shikh; Costantino Pitzalis
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.